Technological advancements in developing novel and next-generation biosensors are driving market progression. The growing demand for point-of-care testing is accelerating the development of miniaturized immunosensors based on the integration of electrochemical and microfluidic technologies.
Advanced biosensors have broad applications in drug discovery, diagnostics, biomedicine, environmental monitoring, food safety, and processing. Additionally, market players are increasingly investing in R&D for wearable medical devices that address fertility issues in women.
For example, Ava Science Inc. developed the Ava Fertility Tracker, a bracelet that uses biosensors to detect the fertility window, sleep quality, and stress levels in women.
Numerous startup companies are focusing on developing advanced wearable products for diagnosing and real-time monitoring of chronic conditions.
Technological advancements allow for the development of easier, portable, and more convenient testing devices, which are increasing adoption rates among insulin-dependent diabetes patients. For instance, the DEXCOM G4 Platinum features an in-built hypoglycemia safety alert, customizable alerts to monitor blood sugar drops, and a water-resistant sensor with an attached transmitter.
Authors:
Mariam Faizullabhoy , Gauri Wani
Frequently Asked Questions (FAQ) :
The global biosensors industry was valued at approximately USD 30.1 billion in 2023 and is estimated to grow at a 7.7% CAGR from 2024 to 2032, driven by the rising global prevalence of diabetes.
The non-wearable biosensors segment held a substantial 64.2% market share in 2023 due to their ease of use, high accuracy, and rapid diagnostic capabilities.
The point-of-care testing (POC) segment is projected to reach USD 29.8 billion by 2032, as biosensors in POC testing provide quick results, crucial for acute conditions and emergencies.
Key players in the industry include Abbott Laboratories, Ascensia Diabetes Care Holdings, Bio-Rad Laboratories, Biosensors International Group, Danaher Corporation, Dexcom, F. Hoffmann-La Roche, LifeScan, Masimo, and Nova Biomedical.